Author pages are created from data sourced from our academic publisher partnerships and public sources.
Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction
- O. Fahmi, Susan I Hurst, +8 authors R. Obach
- Chemistry, Medicine
- Drug Metabolism and Disposition
- 1 August 2009
Cytochrome P450 3A4 (CYP3A4) is the most important enzyme in drug metabolism and because it is the most frequent target for pharmacokinetic drug-drug interactions (DDIs) it is highly desirable to be… Expand
Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction.
- K. Youdim, Aref Zayed, +10 authors R. Obach
- Chemistry, Medicine
- British journal of clinical pharmacology
- 1 May 2008
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT Numerous retrospective analyses have shown the utility of in vitro systems for predicting potential drug-drug interactions (DDIs). Prediction of DDIs from in… Expand
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET)
We evaluated the efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately controlled (HbA1c, 7.0%‐10.5%) with metformin monotherapy (≥1500 mg/d for ≥8… Expand
Evaluation of Cognitive Function in Healthy Older Subjects Treated with Fesoterodine
Abstract Objective: To evaluate the cognitive effects of fesoterodine 4 and 8 mg versus placebo in healthy older adults. Methods: This was an active– and placebo–controlled, double–blind,… Expand
Flexible‐Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double‐Blind, Placebo‐Controlled Study of Fesoterodine in an Aging Population Trial
- A. Wagg, V. Khullar, +6 authors I. Osterloh
- Journal of the American Geriatrics Society
- 1 February 2013
To assess the efficacy and safety of flexible‐dose fesoterodine in elderly adults with overactive bladder (OAB).
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone
To conduct a phase III study to evaluate the efficacy and safety of ertugliflozin monotherapy in people with type 2 diabetes.
EVALUATION OF THE SENSITIVITY OF URETHRAL PRESSURE REFLECTOMETRY (UPR) AND URETHRAL PRESSURE PROFILOMETRY (UPP) TO DETECT PHARMACOLOGICAL AUGMENTATION OF URETHRAL PRESSURE, USING [S,S]-REBOXETINE
Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated Phase I study
Abstract Background Inclusion of cognitive assessment in Phase I trials of novel pharmaceutical agents may help identify subtle yet meaningful CNS effects early in clinical development, and lead to a… Expand
Long‐term safety, tolerability and efficacy of flexible‐dose fesoterodine in elderly patients with overactive bladder: Open‐label extension of the SOFIA trial
- A. Wagg, V. Khullar, M. Michel, M. Oelke, A. Darekar, C. Bitoun
- Neurourology and urodynamics
- 1 January 2014
To assess the long‐term safety, tolerability, and efficacy of flexible‐dose fesoterodine in elderly patients with OAB.
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
- R. Aronson, J. Frias, Allison Goldman, A. Darekar, B. Lauring, S. Terra
- Diabetes, obesity & metabolism
- 23 February 2018
This phase III, multicentre, randomized study (ClinicalTrials.gov; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes… Expand